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Abstract
Arrayed CRISPR-based screens emerge as a powerful alternative to
pooled screens making it possible to investigate a wide range of
cellular phenotypes that are typically not amenable to pooled
screens. Here, we describe a solid-phase transfection platform that
enables CRISPR-based genetic screens in arrayed format with flex-
ible readouts. We demonstrate efficient gene knockout upon
delivery of guide RNAs and Cas9/guide RNA ribonucleoprotein
complexes into untransformed and cancer cell lines. In addition,
we provide evidence that our platform can be easily adapted to
high-throughput screens and we use this approach to study onco-
gene addiction in tumor cells. Finally demonstrating that the
human primary cells can also be edited using this method, we pave
the way for rapid testing of potential targeted therapies.
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Introduction
The ongoing development of tools for targeted genome editing using
CRISPR (clustered regularly interspaced short palindromic repeat)
has revolutionized functional genomics (Shalem et al, 2015). To
date, CRISPR-based forward genetic screens in pooled format have
largely been used to study gene essentiality and synthetic lethality
in different contexts (Shalem et al, 2014; Hart et al, 2015; Wang
et al, 2015, 2017). These screens are largely restricted to measuring
growth phenotypes or to phenotype/cellular markers that can be
selected by fluorescence-activated cell sorting (FACS) and require
next-generation sequencing (NGS) based readouts to analyze the
data. In contrast, using fluorescence, luminescence, or imaging-
based assays, arrayed screens can be used to study a wider range of
cellular phenotypes such as cellular morphology, cell cycle stage,
and protein or mRNA localization (Henser-Brownhill et al, 2017; de
Groot et al, 2018). So far, a number of arrayed screens were
described using viral-based transduction methods where each well
on a multi-well plate is transduced with a virus that can integrate
into the cells (Hultquist et al, 2016; McCleland et al, 2016; Datlinger
et al, 2017). This experimentally tedious procedure can introduce
potential biases since each viral MOI needs to be calculated to make
sure each cell received the same amount of virus and an antibiotic
selection is required to enrich for transduced cells. Since viral-based
transduction strategies can be laborious for arrayed screens, a good
alternative is the use of synthetic gRNA complexes that can be
directly transfected into Cas9 protein-expressing cells (Shalem et al,
2015). However, classical lipofection-based methods may suffer
from high variation between individual experiments and their
success largely depends on the cell line. As an alternative, the first
idea of spotting nucleic acids onto solid surfaces was implemented
by Ziauddin & Sabatini (Ziauddin & Sabatini, 2001) where different
cDNAs were spotted onto glass slides. In these slides, eGFP expres-
sion measurements led to the discovery of gene functions involved
in tyrosine kinase signaling, apoptosis, and cell adhesion. This idea
gave rise to further developments such as siRNA microarrays,
which were implemented to discover genes involved in cytokinesis,
and proteasome-mediated proteolysis (Silva et al, 2004) as well as
in combination with high-content microscopy revealed mitotic
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phenotypes and regulators of secretory pathway in HeLa cells (Neu-
mann et al, 2010; Simpson et al, 2012). While being instrumental
for the development of high-throughput arrayed screens that
allowed the investigation of cellular physiology as well as cytotoxic-
ity and drug screening, microarrays are typically limited to imaging-
based readouts and use only a few numbers of cells per spot. Thus,
an efficient delivery system applicable to a wide range of cell types
with various readouts is missing. Here, inspired by previous meth-
ods using cDNA (Ziauddin & Sabatini, 2001) or siRNA (Erfle et al,
2008) we developed a solid-phase transfection platform that facili-
tates arrayed CRISPR screens in multi-well plates enabling low cyto-
toxicity and high efficiency with various readouts such as
microscopy, flow cytometry, and ATP-based viability measure-
ments. We demonstrate successful delivery of synthetic guide RNAs
to 20 different Cas9-expressing cell lines. In addition, we establish
delivery of Cas9:guide RNA ribonucleoprotein (RNP) complexes to
cancer cell lines and we provide evidence that our platform is suit-
able to study oncogene addiction in tumor cell lines. Finally, we
provide evidence that not only cancer cell lines, but also primary
cells can be edited by using epithelial cells from lung adeno- and
squamous cell carcinoma patients. Taken together, we provide a
novel platform for rapid testing of potential targeted therapies.
Results and Discussion
Establishment of solid-phase transfection with gRNAs
In solid-phase transfection, the microwell plates are coated with
the transfection reagent and the synthetic crRNA:tracrRNA
complexes (hereafter referred to as gRNAs) that are stabilized by
sucrose and gelatin. Freeze-dried plates with these complexes can
either be stored for long periods of time or can directly be used by
seeding cells on these pre-coated plates (Fig 1). As a proof-of-
principle, we first established and used our solid-phase transfec-
tion platform to target genes with gRNAs in cell lines expressing
Cas9. We used TP53-deficient RPE-1 cells with doxycycline-indu-
cible Cas9 expression (hereafter referred to as RPE-1) (Fig EV1)
and tested four target genes that exhibit clear phenotypes upon
disruption that can be followed by microscopy, assessing either
the changes in the nuclear morphology; PLK1, CCNA2 or measur-
ing the loss of signal after antibody staining; GOLGA2 and MKI67
(Fig 2).
1 Plk1 is a cell cycle kinase with various functions in mitotic
spindle formation (Sumara et al, 2004). Consistent with this role,
RPE-1 cells transfected with a gRNA targeting PLK1 accumulated
in prometaphase already 24 h after transfection (Fig 2A), indicat-
ing a cell cycle arrest, followed by cell death after 72 h. Notably,
the phenotypic penetrance was similar to PLK1 knockdown by
siRNA (Fig EV2A–C).
2 Cyclin A is known to have dual role in controlling the cell cycle
by the activation of cyclin-dependent kinases and has been
shown to be involved in initiation of DNA replication and mitotic
entry (Pagano et al, 1992). We transfected cells with a gRNA
targeting CCNA2 and followed the cells after 72 h of transfection.
Consistent with its siRNA knockdown phenotype (Neumann
et al, 2010), knockdown of CCNA2 by solid-phase transfection of
gRNA resulted in a marked increase in the number of cells with
large nuclei (Fig 2B and C).
3 Golga2 is a well-established Golgi marker (Nakamura et al,
1995). We transfected the gRNAs targeting GOLGA2 locus
(Fig EV2D) and assessed GOLGA2 protein levels by immunofluo-
rescence and observed a marked decrease in Golga2 protein
levels 72 h after transfection (Fig 2D and E).
4 Ki67 is a marker of proliferating cells (Gerdes et al, 1984). We
measured the levels of Ki67 in the nuclei by immunofluorescence
as well as by FACS (Figs 2F and EV2E). Upon 72 h of
gRNA : tracrRNA
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Figure 1. Workflow for solid-phase transfection.
(i) In solid-phase transfection, the microwell plates are coated with the transfection mixes consisting of synthetic gRNAs, lipid reagent, sucrose, and gelatin. The microwell
plates are then freeze dried and can either be stored for long periods of time or (ii) the cells can directly be seeded on these pre-coated plates. A wide range of readouts such as
microscopy, flow cytometry, or cell viability assays is possible.
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Figure 2. Solid-phase transfection for delivery of synthetic guide RNAs.
A Solid-phase transfection of nontargeting (scrambled) or PLK1 targeting gRNAs into Cas9-expressing RPE-1TP53/ cells. Cells were fixed after 24, 48, and 72 h and
imaged after DNA staining with Hoechst. Green arrowheads indicate examples of prometaphase-arrested cells, and the red arrowheads indicate examples of dead
cells due to Plk1 downregulation. Phenotypic penetrance is indicated at the top of each panel with standard deviation derived from two independent experiments.
Scale bar, 20 lm.
B Solid-phase transfection of nontargeting (scrambled) or CCNA2 targeting gRNAs into Cas9-expressing RPE-1TP53/ cells. Cells were fixed after 72 h and imaged after
DNA staining with Hoechst. Red arrowheads indicate large nuclei, a typical phenotype observed after CCNA2 depletion. Scale bar, 50 lm.
C Quantification of nuclear size measurements from (B). Data derived from three independent experiments. P value (scrambled versus CCNA2) < 2
e16, Kolmogorov–Smirnov
test.
D Solid-phase transfection of nontargeting (scrambled), GOLGA2 targeting gRNA complexes into Cas9-expressing RPE-1TP53/ cells. Cells were fixed after 72 h, stained
with Golga2 antibody (red), and Hoechst (blue) to mark DNA and imaged. Scale bar, 50 lm.
E Quantification of experiments in (D). Data derived from three independent experiments. Data is represented as violin plots merged with boxplots that extends
from min to max with the probability density. Boxes indicate 25th and 75th percentiles. Black lines indicate median values. P value (scrambled versus GOLGA2) < 2
e16,
Mann–Whitney U test.
F Solid-phase transfection of nontargeting (scrambled), MKI67 targeting gRNA complexes into Cas9-expressing RPE-1TP53/ cells. Cells were fixed after 72 h, stained
with Ki67 antibody (red), and Hoechst (blue) to mark DNA and imaged. Scale bar, 50 lm.
G Quantification of experiments in (F). Data derived from three independent experiments. P value (scrambled versus MKI67) < 2
e16, Mann–Whitney U test. Data is
represented as violin plots merged with boxplots that extends from min to max with the probability density. Boxes indicate 25th and 75th percentiles. Black lines
indicate median values.
H Comparison of phenotypic penetrance with liquid- and solid-phase transfection. RPE-1, HEK293T, NCI-H358, and NCI-N87 cells were transfected with scrambled or
POLR2A targeting gRNAs in two different cell numbers (2,250 or 20,000 cells/well). Five days post-transfection, cell viability was measured by CellTiter-Glo. Boxplots
represent values from at least three independent experiments containing three technical replicates. In the boxplots, centerlines mark the medians, box limits indicate
the 25th and 75th percentiles, and whiskers extend to 5th and 95th percentiles.
I Cell viability measurements after solid-phase transfection targeting POLR2A in a panel of cell lines. Cas9-expressing cell lines were transfected with scrambled and
POLR2A targeting gRNA, and cell viability was assessed after 5 days. The raw values are background subtracted and normalized to the mock controls. Results are from
at least three independent experiments containing three technical replicates. In the boxplots, centerlines mark the medians, box limits indicate the 25th and 75th
percentiles, and whiskers extend to 5th and 95th percentiles. For all cell lines, P values (scrambled versus POLR2A) < 0.005. Mann–Whitney U test.
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transfection of gRNAs targeting MKI67 gene, we have observed a
very significant reduction in Ki67 levels (Fig 2G). Altogether,
these data suggest that solid-phase transfection platform is suit-
able for screens with phenotypic readouts.
After establishing several markers that can be followed up by
imaging-based assays in RPE-1 cells, we wondered whether we can
extend and apply this system to additional cell lines and for that we
wanted to use a rapid, viability-based readout that is compatible
with experiments in higher throughput in several different cell lines.
To this end, we examined the outcome of POLR2A disruption by a
luminescence-based cell viability assay measuring cellular ATP
levels. POLR2A is an essential gene that encodes a subunit of the
RNA polymerase II (Young, 1991). Consistently, its disruption led to
an 85% reduction in cell viability compared to a nontargeting
(scrambled) gRNA (Fig EV2F). We confirmed the specificity of
POLR2A targeting first at the DNA level by demonstrating the
correct targeting of the POLR2A locus (Fig EV2G). Second, we
measured the POLR2A protein levels in the nucleus by immunofluo-
rescence. We observed a time-dependent and significant decrease in
the POLR2A protein levels, consistent with the previously reported
40-h half-life of POLR2A (McShane et al, 2016) (Fig EV2H and I).
These results suggest that solid-phase transfection has the potential
to be applied to viability-based assays.
High-throughput arrayed screens require minimal handling after
transfection to reduce potential biases. For this reason, an impor-
tant prerequisite for these screens would be to be able to transfect
low number of cells with minimal cytotoxicity. We have observed
that with liquid transfection some cell lines such as RPE-1 can be
efficiently transfected when low number of cells was seeded (2,500
cells/well) as previously reported in the literature for other cell
lines (Tan & Martin, 2016; Strezoska et al, 2017; de Groot et al,
2018). However, some cell lines such as NCI-H358, NCI-N87, or
HEK293T that also express doxycycline-inducible Cas9 (Fig EV1)
suffer from increased cytotoxicity and high variability under the
same conditions. Since different cell lines may respond differently
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Figure 3. Solid-phase transfection for delivery of Cas9/guide RNA ribonucleoprotein complexes.
A Solid-phase transfection of nontargeting (scrambled) or CCNA2 targeting RNP complexes into WT RPE-1TP53/ cells. Cells were fixed after 72 h and imaged after DNA
staining with Hoechst. Scale bar, 50 lm.
B Quantification of experiments in (A). Data derived from two independent experiments. P value (scrambled versus CCNA2) < 2
e16, Kolmogorov–Smirnov test.
C Solid-phase transfection of nontargeting (scrambled), MKI67 targeting RNP complexes into WT RPE-1TP53/ cells. Cells were fixed after 72 h, stained with Ki67
antibody (red), and Hoechst (blue) to mark DNA and imaged. Scale bar, 50 lm.
D Quantification of experiments in (C). Data derived from two independent experiments. Data is represented as violin plots merged with boxplots that extends from
min to max together with the probability density. Boxes indicate 25th and 75th percentiles. Black lines indicate median values. P value (scrambled versus MKI67) < 2
e16,
Mann–Whitney U test.
E Four cell lines were transfected with RNP complexes with scrambled or POLR2A targeting gRNA. 5 days post-transfection, cell viability in each well was measured.
Results are from at least three independent experiments containing three technical replicates. In the boxplots, centerlines mark the medians, box limits indicate the
25th and 75th percentiles, and whiskers extend to 5th and 95th percentiles. For all cell lines, P values (scrambled versus POLR2A) < 0.005. Mann–Whitney U test.
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to changing transfection conditions, we next tested whether solid-
phase transfection can be used as a universal strategy to perform
arrayed screens in multiple cell lines. Using solid-phase transfection
in these cell lines, we observed 70–90% cell death when targeting
POLR2A with little effect on cell fitness with a nontargeting scram-
bled gRNA (Fig EV3A). In addition, we showed that the general fit-
ness of the cells remained unaffected even after storage of the
lyophilized plates at room temperature or using another set of
control gRNAs that target either nonessential genes or intergenic
regions (Fig EV3B and C). Next, we compared solid-phase transfec-
tion to commonly used methods of liquid-phase transfection. In all
tested cell lines, our solid transfection protocol performed best
when low number of cells (2,250 cells/well) was seeded. In this
case, the transfection efficiencies were similar to that of liquid
transfection with high number of cells (20,000 cells/well); however,
these high numbers are incompatible with prolonged culturing of
cells for downstream applications (Fig 2H). These data suggest that
when low number of cells is seeded, the solid-phase transfection
allows for the arrayed CRISPR screens to be carried out in an effi-
cient manner for extended periods of time without the need of addi-
tional handling steps.
To further validate these results in other cell models, we next
generated and tested 16 additional Cas9-expressing cell lines
(Fig EV1 and Table EV1) and assessed the effect of targeting
POLR2A on cell viability. In all these cell lines, we repeatedly
observed phenotypic penetrance above 50%, with 10 cell lines
reaching median efficiencies above 70% while showing minimal
cytotoxicity after scrambled gRNA transfection (Figs 2I and EV3D).
In conclusion, our platform is suitable for targeted gRNA screens in
a wide range of Cas9-expressing cell lines.
RNP complexes can be used in solid-phase transfection
Stable inducible Cas9 expression in cells might not always be avail-
able, and exogenous expression of Cas9 can be disadvantageous in
certain settings. Thus, we tested the compatibility of our platform
with RNP complex transfection. To this end, using previously estab-
lished markers that can be followed by imaging-based assays, we
transfected RPE-1 cells with RNP complexes targeting CCNA2 and
MKI67 to assess changes in nuclear morphology and reduction in
protein levels, respectively. In the case of CCNA2, consistent with
the phenotype of the gRNA transfection, we observed an increased
rate of cells with large nuclei at 72 h post-transfection (Fig 3A and
B). For Ki67, we also observed a marked reduction in the protein
levels by immunofluorescence suggesting that solid-phase transfec-
tion can deliver RNP complexes that can be assessed by phenotypic
readouts (Fig 3C and D). In addition, we tested the efficiency of
POLR2A targeting using RNPs. In wild-type HEK293T, NCI-N87, and
NCI-H358 cells, we observed up to 90% loss in cell viability upon
transfection of RNP complexes targeting POLR2A (Fig 3E), demon-
strating the ability of solid-phase transfection platform to deliver
RNPs to several cancer cell lines.
Solid-phase transfection can be easily adapted to
high-throughput screens
The ability to transfect a broad range of cell types with minimal cyto-
toxicity allowed us to directly adapt the solid-phase platform to high-
throughput screens. For this, we designed a multi-well plate where
we individually targeted a panel of known oncogenes or kinases that
are reported to be misregulated in human tumors along with
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Figure 4. Arrayed CRISPR screens using solid-phase transfection.
A Viability of NCI-N87 and NCI-H358 cells upon transfection of 45 different gRNAs by solid-phase transfection. Cas9-expressing NCI-N87 and NCI-H358 cells were
seeded on pre-coated plates. Five days post-transfection, cell viability in each well was measured by CellTiter-Glo. Values were background subtracted, normalized
to scrambled controls, and plotted against each other. Blue dots represent scrambled controls, whereas the yellow dots represent POLR2A gRNAs. Green dots
represent the genes that affect the viability in a cell line-dependent manner. Results are representative of three independent experiments.
B, C Logarithm of the odds (LOD) scores of cancer-associated gene KOs in NCI-N87 and NCI-H358 cells derived from screens with gRNAs (B) and RNPs (C). Bottom panels
show distribution of positive (POLR2A) and negative (scrambled) controls for each experiment. LOD score of 3 is highlighted with a dashed line, indicating statistical
significance.
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scrambled and POLR2A control gRNAs (Table EV2) (Higgins et al,
2007; Davoli et al, 2013). With this target panel, we tested the poten-
tial oncogene addiction of two Cas9-expressing cell lines, namely
NCI-H358 and NCI-N87 cells. In both cell lines, POLR2A gRNAs
caused a significant decrease in cell viability, whereas transfection of
the scrambled gRNAs had minimal effects, indicating functional posi-
tive and negative controls in our assay system. NCI-H358 cells carry
a constitutive activating mutation in the KRASG12C gene, whereas
NCI-N87 have a copy number amplification of the ERBB2 gene (Tate
et al, 2019). Thus, we predicted that these cell lines would show
survival dependency on KRAS and ERBB2, respectively (Pagliarini
et al, 2015) (Fig 4A). For the majority of target genes in our panel,
the effect of individual gRNAs on viability was similar in both of the
cell lines. Strikingly, we observed loss of cell viability upon KRAS
and ERBB2 disruption in NCI-H358 and NCI-N87 cell lines, respec-
tively (Figs 4A and EV4). Although it is now acknowledged that high
copy numbers affect the viability of the cells when targeting these
regions by gRNAs and ERBB2 dependency may be confounded by
this effect (Aguirre et al, 2016; Munoz et al, 2016), the dependency
on KRAS does stem from an activating mutation, thus is directly a
measure of the oncogenic activity of KRAS that the cells rely on.
These data suggest that our system is suitable to detect specific
dependencies arising from genomic alterations in cancer cells.
To normalize screening results from different cell lines and to
correct for the effect of individual gRNAs, we developed a scoring
system based on the logarithm of the odds (LOD), which is a statisti-
cal test often used for linkage analysis in populations (Morton,
1955) (Fig EV5A–C). In our case, the LOD score compares the likeli-
hood of the phenotype of a gene KO to be similar to that of POLR2A
(our positive control that causes lethality when knocked out) over
the likelihood that the phenotype of the gene KO is similar to our
negative controls (scrambled gRNA) based on the assumption of
normally distributed control values. A LOD score of 3 means that
the likelihood of a gene KO behaving similarly to POLR2A is 1,000
times higher than the likelihood of a gene KO behaving similar to
the scrambled control; thus, a high LOD score is an indication of a
gene KO behaving similarly to POLR2A KO, that is causing loss of
cell viability. LOD calculation revealed that genes affecting mitotic
division, such as WEE1 and PLK1 (Neumann et al, 2010), had LOD
scores of > 5 in both cell lines (Fig 4B). In addition, we observed
KRAS and ERBB2 had the highest LOD scores in NCI-H358 and NCI-
N87 cells, respectively. Thus, we conclude that our platform allows
prediction of genotype-specific lethalities in cancer cells due to
oncogene addiction.
We next asked whether we could obtain comparable results also
with solid-phase RNP transfection. For this, we used NCI-H358 and
NCI-N87 cells that do not stably express Cas9. Indeed, similar to
gRNA transfection, RNP transfection produced high LOD scores for
key cell cycle regulators WEE1 and PLK1 in both cell lines. Further-
more, ERBB2 LOD score was among the highest in NCI-N87 cells
and KRAS LOD score was the highest in NCI-H358 cells (Figs 4C
and EV4). These data are consistent with the experiments performed
in Cas9-expressing cells transfecting the gRNA complexes, thus
showing that solid-phase RNP transfection is an alternative and effi-
cient approach for arrayed CRISPR/Cas9 screens.
Primary cells can be edited by solid-phase transfection of
RNP complexes
One potential application of our platform can be in assessment of
targeted therapies. Solid-phase transfection can be used as a rapid
way to find the vulnerabilities of certain tumors, if the cells derived
from patient samples can also be efficiently transfected. In order to
pave the way of using this methodology in targeted therapy, we
HL
F-
1
HL
F-
2
LA
D-
1
LS
C-
1
LS
C-
2
48 hours
4
8
12
%
Pr
om
et
ap
ha
se
 c
el
ls
0
H
LF
-1
LA
D
-1
R
PE
-1
H
LF
-1
LA
D
-1
R
PE
-1
72 hours
LA
D
-1
R
PE
-1
H
LF
-1
Scrambled RNP POLR2A RNPScrambled RNP PLK1 RNP
0
50
100
150
%
Vi
ab
le
 C
el
ls 
A B
Figure 5. Solid-phase transfection in primary cells derived from human tumors.
A Solid-phase transfection of nontargeting (scrambled) or PLK1 targeting RNP complexes into human primary lung fibroblasts (HLF-1), primary lung adenocarcinoma
cells (LAD-1), or RPE-1TP53/ cells. 72 hours post-transfection, cells were stained with Hoechst and imaged. Boxplots represent values from three independent
experiments containing three technical replicates. For all cell lines, P values (scrambled versus Plk1) < 0.05. In the right panels, representative images for each cell line are
shown after RNP transfection targeting PLK1. Arrowheads indicate the cells that are arrested in prometaphase due to Plk1 downregulation. Scale bars indicate 20 lm.
In the boxplots, centerlines mark the medians, box limits indicate the 25th and 75th percentiles, and whiskers extend to 5th and 95th percentiles. Mann–Whitney U test.
B Two human primary lung fibroblasts (HLF) and three primary tumor cell lines derived from patients suffering from either lung squamous carcinoma (LSC) or lung
adenocarcinoma (LAD) were transfected with RNP complexes with scrambled or POLR2A targeting gRNA. Five days post-transfection, cell viability in each well was
measured. Results are from at least three independent experiments containing three technical replicates. In the boxplots, centerlines mark the medians, box limits
indicate the 25th and 75th percentiles, and whiskers extend to 5th and 95th percentiles. For all cell lines, P values (scrambled versus POLR2A) < 0.005. Mann–Whitney U test.
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tested whether we can also target primary cells by solid-phase
transfection of RNP complexes. To this end, we transfected PLK1
targeting RNP complexes into human primary lung fibroblasts
derived from lung parenchyma as well as primary lung adenocarci-
noma cells and compared these results to RPE-1 cells. In both RPE-
1 cell line and the primary cells, we observed an increased rate of
mitotic arrest at 48 h post-transfection (Fig 5A). In addition, we
transfected POLR2A targeting RNP complexes to two human
primary lung fibroblasts and three primary tumor cell lines derived
from patients suffering from either lung squamous carcinoma or
lung adenocarcinoma. Although in some of these primary cells we
observed slightly higher levels of cytotoxicity due to transfection,
the loss of viability due to transfection of POLR2A targeting RNPs
was consistently and significantly higher (Fig 5B). Our results
demonstrate that solid-phase transfection platform can be compati-
ble with RNP delivery not only in cancer cell lines but also in
human primary cancer cells.
In summary, we developed a solid-phase reverse transfection
method that allows efficient delivery of either synthetic gRNAs or
Cas9 containing RNP complexes. Our system has several advan-
tages over previous delivery approaches for screening purposes
(Tan & Martin, 2016; Bulkescher et al, 2017; Strezoska et al,
2017). First, the transfection complexes can be easily and effi-
ciently coated onto the plates, and ready-to-use plates allow
flexibility in designing experiments. Second, multiple plates can
be produced from one transfection mix, eliminating potential
batch effects across different experiments. Finally, a wide range of
cell lines can be directly seeded on coated plates which allow
several downstream applications such as viability measurements
or microscopy-based readouts. This reduces potential biases
caused by additional handling steps and allows easy automation.
However, we also note couple of limitations in our system. For
instance, solid-phase transfection requires additional equipment
for freeze drying the transfection mixes and it can only be applied
to adherent cells. In addition, due to the time required for the
observation of certain phenotypes, solid-phase transfection of
gRNAs may be limited to gene products that have fast turnover
rates. Arrayed screens need to be completed in a shorter time
frame than that of the pooled screens that allow cells to be kept
in culture longer time. Currently, with a maximum time frame of
5 days post-transfection, only proteins with fast turnover can be
efficiently targeted. To estimate how many proteins can be effi-
ciently targeted by CRISPR/Cas9-based methods such as solid-
phase transfection, we utilized the recent study measuring the
protein turnover rates in RPE-1 cells. Assuming most of the exper-
iments should be carried out in 3–5 days post-transfection, we
predict that at least in RPE-1 cells phenotypes of approximately
17.7% of the proteins may not be efficiently visualized due to
their long half-lives (> 120 h) (Fig EV5D). For this reason, we
note that a careful assessment of protein turnover rates should be
included in experimental design.
Targeted therapy is a powerful concept based on vulnerabilities
or addictions of tumors. Although genome, exome sequencing,
and expression analysis of oncogenes provide detailed information
about the patients, methods that can experimentally test these
predictions in a systematic manner are not well-established. Using
our solid-phase CRISPR screening platform, we demonstrate effi-
cient delivery of RNP complexes in untransformed cells, two
cancer cell lines, human primary lung fibroblasts, and primary
tumor epithelial cells. With high flexibility regarding targets and
assays, our platform can contribute to future CRISPR-based
biomedical applications.
Materials and Methods
Reagents and Tools table
Reagent/resource Reference or source Identifier or catalog number
Experimental models
List of cell lines Table EV1
Synthetic RNA and Recombinant Cas9 protein
A list of synthetic RNA used in this study was detailed in Table EV1 IDT N/A
Sp. Cas9 tracrRNA IDT 1072533
Antibodies
Anti-POLR2A (Rabbit) Sigma HPA021503
Anti-GM130 (GOLGA2) (Mouse) BD 610822
Anti-Cas9 Cell Signaling CST #14697
Anti-GAPDH Cell Signaling CST #5174
Anti-Ki67 eBioScience 14-5698-82
Anti-CyclinA Santa Cruz sc-751
Anti-Rabbit AlexaFlour-488 Secondary Antibody Thermo Fisher A21206
Anti-Mouse AlexaFlour-568 Secondary Antibody Thermo Fisher A11004
Anti-Mouse AlexaFlour-488 Secondary Antibody Thermo Fisher A11034
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Reagents and Tools table (continued)
Reagent/resource Reference or source Identifier or catalog number
Virus particles
hEF1a-TurboGFP-Cas9 Nuclease Dharmacon VCAS11864
hCMV-TurboGFP-Cas9 Nuclease Dharmacon VCAS11868
Oligonucleotides and sequence-based reagents
Golga2_5 PCR primer (IDT) CACTTGCTTGGGTTTCCTCC
Golga2_6 PCR primer (IDT) AGCAACCACACACAAAAGCA
Plk1_5 PCR primer (IDT) AGAGAAACCCACCAAGACCC
Plk1_6 PCR primer (IDT) TGACTTGTGGGTTGTCTCCT
Polr2a_3 PCR primer (IDT) CAAACTGCCGTAACCTCTGC
Polr2a_4 PCR primer (IDT) GACTCCCTAGGATTCGTCGG
pCW-Cas9 AddGene #50661
psPAX2 AddGene #12260
pMD2.G AddGene #12259
Chemicals, enzymes and other reagents
Recombinant Sp. Cas9 protein IDT 1081059
Lipofectamine RNAimax Thermo Fisher 13778075
Lipofectamine 2000 Thermo Fisher 11668-019
Gelatin Sigma G3931
Sucrose Roth 4621-1
RNA and DNase free water Thermo Fisher 4387936
Q5 Hot Start High Fidelity 2X Master Mix New England Biolabs M0494
Surveyor mutation detection kit IDT 706020
CellTiter-Glo Promega G7573
Doxycycline Hydrochloride Sigma D3072
Pre-cast Polyacrylamide Gel Mini-Protean TGX Bio-Rad
RIPA Buffer Cell Signaling CST-9806S
Sytox Blue Molecular Probes S34857
Opti-MEM Thermo Fisher 31985-062
Hexadimethrine Bromide Sigma H9268-5G
Bovine Serum Albumin Roth 3737.3
Triton X100 Sigma X100-500
Fetal Bovine Serum Gibco 10270106
ACK Lysis Buffer Sigma Aldrich A1049201
Penicilin/Streptomycin (PS) Fisher Scientific 15140122
Amphotericin B Fisher Scientific 15290026
HBSS Fisher Scientific 14175053
HS DNA Kit Agilent 5067-4626
QuickExtract Epicentre QE09050
Software
R-base https://www.r-project.org 3.5.0
FiJi/ImageJ https://fiji.sc/ 2.0/1.2
ZenLite Microscope Software https://www.zeiss.com 3.0
Cell Profiler https://cellprofiler.org/ 2.2.1
KNIME https://www.knime.com 4.0.2
ShinyHTM https://github.com/embl-cba/shinyHTM
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Reagents and Tools table (continued)
Reagent/resource Reference or source Identifier or catalog number
Culture and coating plates
Flat Bottom Black 96-well plates Zellkontakt 655090
Flat Bottom Glass Black 96-well plates Cellvis P96-1.5H-N
Flat Bottom White 96-well plates Costar 3903
Flat Bottom transparent 96-well plates Eppendorf 0030730119
Equipment
Vacuum Centrifuge MiVac QUC-23050-B00
FACSAria II Becton Dickinson
Glomax Multi+ Promega
Western Blot Transfer Bio-Rad Trans-Blot Turbo
Odyssey System LI-COR Biosciences
BioAnalyzer Agilent 2100
Cell/Particle Counter Beckman-Coulter Z2
Multidrop Combi Microplate dispenser Thermo Fisher 836
Tumor Dissociation Kit Miltenyi Biotec 130-095-929
Evos FL Microscope Thermo Fisher
Zeiss Ax10 Observer D1 fluorescence microscope Zeiss
Automated Epifluorescent Microscope Nikon Ti-E
Other
Silica Desiccant Beads NeoLab 1-7301
Cell Strainer BD Falcon 352350
Methods and Protocols
Cell lines and treatments
A table detailing cell line media, supplements, and source informa-
tion can be found in the Table EV1.
Generation of Cas9-expressing cell lines
Stable and/or inducible expression of Cas9 in cancer cell lines was
achieved by lentiviral transduction of Cas9-encoding plasmids. For
generating the viruses for the doxycycline-inducible expression of
Cas9, HEK293T cells were co-transfected with pCW-Cas9, psPAX2,
and pMD2.G plasmids (Addgene). 72 hours post-transfection, super-
natant of HEK293T cells was collected and filtered using 44 lm ster-
ile filter. The relevant cell lines were infected with the 50 ll virus
containing supernatant and 8 lg/ml Hexadimethrine Bromide
(Sigma). Inducible Cas9-expressing cells were selected with 8 lg/ml
puromycin until uninfected cells are eliminated. Cas9 expression
was assessed in puromycin-resistant clones by immunofluorescence
upon 1 lg/ml doxycycline induction. NCI-H1703, OVCAR-8, and RD
cell lines were infected with Cas9 lentiviral particles from Dharma-
con (VCAS11868), and MDA-MB-157 cell line was infected with
Dharmacon (VCAS11864) with a multiplicity of infection of 0.1.
GFP-positive cells were sorted twice to achieve maximum purity.
Liquid-phase transfection
Exponentially proliferating cells at 70–80% confluency were trans-
fected with 2.5 pmol gRNA complexes and 0.3 ll of Lipofectamine
RNAiMax (Invitrogen 13778150) according to the manufacturer’s
protocols. Culture media were replaced 12 h after transfection
mixture was added. Transfected or control group cells were split
1:10 into a new flat bottom 96-well plate (Costar 3903) on the
second day following transfection.
Preparation of CRISPR transfection mixes using solid-phase
transfection
Annealing of gRNAs
In order to prepare 3.3 lM gRNA complexes, 1 ll from the stock
solutions of 100 lM cRNA and tracrRNA was added to 28 lls of
duplexing buffer (IDT), heated at 95°C for 95 for 5 min. After the
incubation, the tubes were left at room temperature for approxi-
mately 20–30 min to cool down.
For each reaction
1 To achieve 2.5 pmol gRNA complexes in each coated well, 3 ll
Opti-MEM/sucrose solution (1.37%w/v) was mixed carefully
eight times with 1.75 ll Lipofectamine 2000 or RNaimax
(Thermo Fisher).
2 6.75 ll of 3.3 lM gRNA mixture was added and carefully mixed
eight times, and the final transfection mix was incubated for
20 min at room temperature.
3 To prepare the gelatin solution, 0.2 g gelatin was dissolved in
100 ml H2O and heated up to 56°C.
4 After incubation of gRNAs with the lipofectamine/Opti-MEM/
Sucrose mix, 7 ll of gelatin (0.2% w/v in water) was added
and carefully mixed 8 times. The final mixture was diluted in
RNA and DNase-free water (Thermo Fisher) 1:25. Dilution
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needs to be done in two steps. The initial dilution step should
not exceed 1/10 of the volume of the transfection mix (18 ll
transfection mix was diluted with 132 ll H2O and mixed eight
times, and then, 350 ll of H2O was added and again mixed
eight times).
5 From this mix, 50 ll to each well of a 96-well plate was plated.
6 Plates were dried using a MiVac vacuum centrifuge (QUC-23050-
B00) accommodating multi-well plates. The MiVac was
preheated to 60°C and was set to 37°C immediately after starting
the device.
7 For 384-well plates, we prepared the same mixtures and plated
15 ll of the final mix to each well of a 384-well plate.
Coating of RNP complexes
For coating of ribonucleoprotein complexes, we mixed 3.3 lM
gRNA: tracrRNA and 3 lM Cas9 protein (IDT) (diluted in Opti-MEM
(GIBCO)) in a 1:1 ratio) and incubated this mixture for 5 min at
room temperature.
RNP complexes were then mixed and incubated with Opti-MEM/
sucrose solution and Lipofectamine RNAimax (Thermo Fisher) as
described above.
Preparation of CRISPR transfection mixes using solid-phase
transfection (96 wells—protocol using Liquidator)
1 2835 ll duplexing buffer was mixed with 105 ll tracrRNA
(from 100 lM stock concentration), and from this mix, 28 ll
was distributed to each well of a 96-well PCR plate with a 12-
channel pipette.
2 2 ll of crRNA complexes was added from the crRNA master
plate to the PCR plate with tracrRNA and duplex buffer.
3 The gRNA mixture was incubated at 95°C for 5 min (PCR
machine).
4 The PCR plate was removed and left on the bench for app 10–
20 min to cool down to room temperature.
5 For a full 96-well plate, 510 ll Opti-MEM/sucrose solution
(1.37%w/v) and 298 ll Lipofectamine 2000 (or Lipofectamine
RNAimax for RNP) were mixed.
6 7 ll from this mixture was pipetted into each well of the 96-well
plate, and the plate was centrifuged shortly and carefully up to
500 rpm.
7 15–30 ll of 0.2% gelatin was pipetted into each well of the 96-
well plate, and the plate was centrifuged shortly and carefully
up to 500 rpm.
8 6.5 ll of gRNA complexes with a concentration of 3.3 lM was
transferred into an empty 96-well plate.
9 5 ll of the transfection reagent source plate containing
Opti-MEM/Sucrose and Lipofectamine 2000 was added to the
plate containing gRNA complexes and mixed eight times. The
plate was centrifuged shortly and carefully up to 500 rpm.
10 Transfection mixes were incubated at room temperature for
20 min.
11 After incubation, 7 ll of gelatin was added and mixed 8 times.
12 81.5 ll nuclease-free H2O was added into a 96-deep-well plate.
13 The transfection mix was added into the 96-deep-well plate and
mixed 8 times with a volume of 50 ll.
14 A total of 350 ll nuclease-free H2O (175 ll pipetted twice) was
added to the 96-deep-well plate and mixed with a volume of
200 ll volume.
15 50 ll of these diluted transfection mixes was transferred into 8
empty 96-well plates.
16 The plates were immediately dried in speed-vac (MiVac). When
drying 8 plates, the following settings were used: The speed-vac
was preheated to 60°C, and then, the temperature was changed
to 37°C immediately after starting the device. (Note: It is impor-
tant to not leave the finished plates outside for too long, as this
may affect the success of the coating process).
17 The ready plates were stored in sealed boxes with silica desic-
cant (drying pearls) for future use. We note that while the
gRNA plates can be stored over long periods of time in these
sealed boxes, the time of storage of RNP complexes should be
tested for each cell line as in some cases we observed loss of fit-
ness after 1 week of storage at room temperature.
Surveyor assay
After medium removal from the cells, lysis was performed directly
in 96-well plates according to the manufacturer’s protocol using
QuickExtract lysis reagent (Epicentre). The cell lysates of the tripli-
cates were collected in one single tube. PCR amplification was done,
using Q5 Hot Start High-Fidelity 2X Master Mix (#M0494, New
England Biolabs) according to manufacturer’s protocol. The enzyme
digest of mispaired dsRNA was done using Surveyor endonuclease
(#M0302, New England Biolabs) according to the manufacturer’s
protocol. The DNA was loaded on bioanalyzer using HS DNA kit.
Viability measurements
For measurements of cell viability, we measured total ATP levels in
96-well plates using CellTiter-Glo Luminescent Viability Assay
(G7573-Promega). An equal volume of DMEM and CellTiter-Glo
(25 ll) was mixed at room temperature immediately before adding
the mix to 96 wells containing adherent cells. Growth media were
fully removed before the addition of 50 ll of CellTiter-Glo mix. Cells
were incubated in a dark environment for 10 min at room tempera-
ture before reading of luminescence using Instinct software with
factory preinstalled settings using GloMax Multi+. Data are exported
to R for further processing. Relative viability values of control
(scrambled) or gRNA transfected were calculated by dividing indi-
vidual raw luminescence measurements to average of no-transfec-
tion (mock) control.
Immunoblotting
Cells HEK293T and RPE-1 are treated with doxycycline (1 lg/ml)
for 24 h. Whole cell extracts of HEK293T and RPE-1 were generated
with RIPA buffer (CST—9806S). Equal amounts of protein (25 lg/
ml) were loaded on a 7.5% precast polyacrylamide gel (Mini-
PROTEAN TGXTM, Bio-Rad). The proteins were then transferred to
a nitrocellulose membrane (Trans-Blot TurboTM, Bio-Rad) using a
transfer apparatus according to the manufacturer’s protocols (Bio-
Rad). After incubation with 10% nonfat milk in TBS-T (10 mM Tris,
pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 30 min, the membrane
was washed three times with TBS-T and incubated with antibodies
against Cas9 (1:1,000, CST #14697) and Gapdh (1:10,000, CST
#5174) at 4°C for 12 h. Membranes were washed three times and
incubated with 1:10,000 dilution of IRDye 680RD and IRDye 800CW
secondary antibodies for 2 h. Blots were washed with TBS-T three
times and developed with the Odyssey system (LI-COR Bios-
ciences).
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Cell seeding, fixation, and immunofluorescence
Cells were trypsinized and were passed through a 70-lm cell
strainer to achieve a single cell suspension, (BD Falcon, 352350).
Cells were counted with a Beckman coulter Z2 particle counter with
10–20 lm setting, and for 96 wells, we seeded 2,250 cells/well using
an automated cell seeder (Thermo Fisher Multidrop combi Micro-
plate Dispenser type 836). For transfection of RNP complexes, an
additional step was used where the cells were shortly centrifuged at
200× g to remove residual trypsin.
Cells stained with Polr2a antibody were seeded in flat bottom 96-
well plates (Zellkontakt, 655090). Cells were fixed with 4% PFA for
10 min, washed with PBS, and then blocked with 10% FBS—0.1%
Triton X-100 for 1 h. Cells were then stained with primary antibody
Anti-Polr2a (1:1,000, Rabbit, Sigma HPA021503) and were incu-
bated in 3% BSA overnight at four degrees. Cells were then washed
3× with PBS and then stained with secondary antibody Alexa-488
(Anti-Rabbit 1:800) and Hoechst (1:4,000) for 1 h at 37 degrees.
Cells were then washed 3× with PBS and then stored in 4 degrees in
the dark until observed under the microscope.
Cells stained with GOLGA2 and Ki67 antibodies were seeded in
96-well glass bottom plates (Cellvis, P96-1.5H-N), fixed for 12 min
with 4% PFA at room temperature, washed three times with D-PBS,
and permeabilized for 12 min at room temperature with 0.5% Triton
X-100 and 1:5,000 Hoechst33342 in D-PBS. Cells were then stained
for 1 h at room temperature (BD, mouse anti GM130 (GOLGA2),
#610822, 1:400) or overnight at 4 degrees (Cell Signaling Technolo-
gies rabbit-anti-Ki67, #D3B5, 1:400) with primary antibody in 0.02%
Triton X-100 in D-PBS, washed three times with D-PBS, and stained
with secondary antibody (Alexa Fluor 568, goat anti mouse, Thermo
Fisher A11004 and Alexa Fluor 488, goat anti-rabbit Thermo Fisher
A11034) 1:400 in 0.02% Triton X-100 in D-PBS for 1 h. Cells were
stored in the dark at 4°C until observed under the microscope.
Microscopy
Images described on Fig EV1B are acquired on an EVOS FL Micro-
scope (Thermo Fisher) equipped with a GFP LED light cube. Images
described on Fig EV1C are acquired on a Zeiss Ax10 Observer D1
fluorescence microscope system equipped with AxioCam and an
HXP 120V lamp, with an Objective Plan-Apochromat 20× and ZEN
acquisition software.
All other fluorescent images are acquired on a Nikon Ti-E auto-
mated epifluorescent microscope. The microscope was equipped
with a DS-Qi2 camera and a Lumencor Sola SE II 365 LED lamp.
The filters sets were provided by Nikon for DAPI (DAPI-5060C),
Alexa Fluor 488 (FITC-3540C), and Alexa Fluor 568 (mCherry C
M343564, Sembrock)). The objectives used were Apo 20× Lambda,
numerical aperture 0.75 (Nikon). We used a hardware-based autofo-
cusing system called the perfect focus system (PFS) from Nikon to
automatically focus the cells in the field of view.
Image analysis
For quantification of Ki67 and Polr2a, images were analyzed by
CellProfiler with custom-made programs. The nuclei were
segmented from DAPI channel image by automated thresholding
and watershed procedure to split touching nuclei. Based on the
segmented nuclei in each image, the mean intensities of the nuclear
Ki67 or POLR2A were measured. For quantification of CCNA2
experiments, the nuclei were segmented as described above in
ImageJ and the areas of the individual segmented nuclei were
measured and plotted.
GOLGA2 levels were automatically measured by specially devel-
oped KNIME workflow. First, the nuclei were segmented from DAPI
channel image by applying median filtration for noise suppression,
automated thresholding, and watershed procedure to split touching
nuclei. Cellular regions were defined by dilating nuclear masks. To
segment of GOLGA2 structures in Alexa 568 channel, top-hat filter
was applied to remove local background followed by automated
thresholding. Total intensity of segmented fragments in Alexa 568
channel was measured for each cell and corrected for background
value estimated from image regions without cells. Additional
measurements for individual cells in DAPI and in Alexa 568 chan-
nels were used to perform follow-up quality control of measure-
ments using shinyHTM software (https://github.com/embl-cba/
shinyHTM). Mitotic cells, out-of-focus cells, and image regions with
unspecific antibody stainings were excluded from the analysis.
Flow cytometry
For isolation of stable Cas9-GFP-expressing cell populations, cells
were sorted using FACSAriaTM II (Becton Dickinson). Cell popula-
tions were gated on a forward (FSC)/side scatter (SSC) plot. Cells
were further gated on forward-area (FSC-A)/forward-height scatter
(FSC-H) plot to determine single cells. Single cells were further
gated on side-area scatter (SSC-A)/(405-450/50A) to determine
living cells based on Sytox Blue (Molecular ProbesTM S34857, 1 lM
final concentration) dead cell staining. Live cells were further gated
to determine eGFP (488-530/30-A) cell populations and sorted using
a 45psi/85lm Nozzle.
For the analysis of Ki67 antibody staining, cells were fixed and
permeabilized directly on 96-well plates using the cell fixation and
permeabilization kit (Abcam). Then, the Ki67 antibody was incubated
with the samples (1:400) overnight at 4°C followed by the incubation
of the secondary antibody coupled to Alexa-488 (Alexa Fluor 488, goat
anti-rabbit Thermo Fischer A11034, 1:1,000) for 1 h at room tempera-
ture. Samples were then analyzed on a FACS LSRFortessaTM mounted
on high-throughput samples (HTS) (BD Biosciences, USA).
Biological samples/patients
Human tissue samples were obtained from lung resections of Cauca-
sian patients that had not received chemotherapy or radiation before
surgery at the Thorax Clinic (Heidelberg, Germany). The protocol for
tissue collection was approved by the ethics committees of the Univer-
sity of Heidelberg and the Ludwig-Maximilians-Universita¨t Mu¨nchen
(reference S-270/2001 333-10 and 17-166). Patients gave informed
consent and remained anonymous in the context of this study.
Fibroblast isolation and expansion
Primary normal human lung fibroblasts (HLF) were isolated by
explant outgrowth from distal airway-free lung tissue obtained from
patients undergoing lung resection due to primary squamous cell
carcinomas (SCC) at the Thoraxklinik (Heidelberg, Germany) (Woo
et al, 2015; Tiran et al, 2017). The explanted tissue was tumor-free
and did not present emphysema, fibrosis, or any inflammatory
changes as shown by histopathology. Moreover, the patients
displayed normal lung function, as determined by spirometry. Cells
were collected from several explant pieces and maintained in DMEM
supplemented with glutamine, penicillin–streptomycin, sodium
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pyruvate, nonessential amino acids, and 2% FBS. Cells were used
within passages 2–4.
Primary tumor cell isolation and culture
Tumor cells were obtained by mechanical and enzymatic dissociation
of dissected squamous cell carcinomas and adenocarcinomas as
follows. Freshly obtained tumors from patients treated at Thoraxklinik
(Heidelberg, Germany) were transported in CO2-independent medium
supplemented with 1% BSA and amphotericin, washed with HBSS,
and minced with sterile razor blade and eye scissors. Tumor pieces
were dissociated into single cell suspensions with the human tumor
dissociation kit following the manufacturer’s instructions (Miltenyi
Biotec, Germany). Enzymatic reaction was stopped by adding 10%
FBS, and single cells were collected by sequential filtering through cell
strainers of 100, 70, and 40 lm (BD Falcon). Cells were centrifuged,
resuspended in ACK lysis buffer (Thermo Fisher), and incubated
3 min at room temperature to lyse erythrocytes. After two washes
with HBSS, cells were resuspended in SAGM (Lonza) supplemented
with 1% FBS. Tumor cells were obtained by differential seeding and
trypsinization and used within passages 1–3.
Calculation of LOD Scores
We calculated LOD scores for the analysis of the oncogene screens.
In these screens, the LOD score is equal to the logarithm to base 10
of the ratio of the probability that the effect of the gRNA is linked to
the effects of POLR2A gRNA(our positive control that causes lethal-
ity when knocked out) to the effect of the gRNA are linked to the
effect of scrambled gRNA (our negative control). Higher LOD scores
are an indication of a gene KO behaving similarly to POLR2A KO,
thus causing loss of cell viability. These probabilities are calculated
based on the assumption that the viability values derived from both
negative and positive controls are normally distributed. In terms of
significance, a LOD score of 3 means the odds are a thousand to one
that the two phenotypes are linked, and this is used as the tradi-
tional LOD score critical value. Using this scoring system, we can
identify gene KOs that are more likely to cause loss of cell viability
across different cancer cell lines and look for similarities and dif-
ferences between different cell lines. There are two important
parameters to determine the quality of a screen: (i) distribution of
controls and (ii) the penetrance of the phenotypes. Higher LOD
scores can be best obtained when the distribution of positive and
negative controls is narrow and well separated. This also serves as a
quality control in our screens as wide and intersecting distributions
will not yield high LOD scores.
Statistical analysis
Statistical tests were performed using Wilcoxon–Mann–Whitney U
test unless stated otherwise. The number of the independent repli-
cates is stated on the figure legends or in the Materials and Methods
Section.
Data availability
Representative raw images of the microscopy-based analyses
described in this study are deposited to BioStudies with the acces-
sion number: S-BSST309.
Expanded View for this article is available online.
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